Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Home
/
update
/
details

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

NextEdge Admin

17 Nov 2024

2 min 21 sec

Syndax Pharmaceuticals announced FDA approval of Revuforj® (revumenib), the first menin inhibitor for treating relapsed or refractory (R/R) acute leukemia with KMT2A translocation in patients aged one year and older. This approval, granted through the FDA’s Real-Time Oncology Review (RTOR) program, follows Breakthrough Therapy, Fast Track, and Priority Review designations.

The efficacy of Revuforj was evaluated in 104 patients from the Phase 1/2 AUGMENT-101 trial. Among these, 21% achieved complete remission (CR) or CR with partial hematological recovery (CRh), with a median duration of 6.4 months. The median time to response was 1.9 months. Additionally, 23% of patients underwent hematopoietic stem cell transplantation after treatment.

Revuforj addresses an unmet need for KMT2A-rearranged acute leukemia, a highly aggressive form with poor prognosis and high relapse rates. Conventional therapies result in a median survival of less than one year, with significantly lower outcomes in later-line settings.

Safety data from 135 patients indicated common adverse reactions, including nausea, infection, musculoskeletal pain, and differentiation syndrome, with low rates of dose reduction (10%) or permanent discontinuation (12%).

Syndax plans to launch 110 mg and 160 mg Revuforj tablets in November 2024 through specialty distributors, with 25 mg tablets for smaller patients available by mid-2025. An oral solution will support expanded access for younger patients until tablet availability.

CEO Michael Metzger emphasized Syndax’s commitment to advancing Revuforj for KMT2Ar acute leukemias, calling it a pivotal step for patients with limited treatment options.